SEC Filing Summary: Know Labs, Inc. (KNW)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Know Labs, Inc. on July 11, 2024. The registrant is a Nevada corporation with principal executive offices in Seattle, Washington. The filing serves as a Regulation FD disclosure regarding the announcement of interim results from the Company's most recent clinical research study.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the disclosure of clinical research updates rather than financial performance data.
Material Changes
The material event reported is the issuance of a press release on July 11, 2024, detailing interim results from a clinical research study. No financial comparisons to prior periods are included in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the clinical study results. The filing explicitly states that the information contained in Item 7.01 and the attached press release (Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings, except as expressly set forth by specific reference. No specific forward-looking guidance, risk factors, or contingencies are detailed within the body of this 8-K form.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Press Release dated July 11, 2024) for specific details on the interim clinical research results.
- Verify the trading status of Common Stock (Symbol: KNW) on NYSE American LLC.
- Confirm that the clinical data has not been incorporated by reference into other regulatory filings unless explicitly stated.
- Check subsequent filings for any financial impact resulting from the clinical study outcomes.